Feferman T - Search Results

1

The transmembrane mutation G380R in fibroblast growth factor receptor 3 uncouples ligand-mediated receptor activation from down-regulation.

Monsonego-Ornan E, Adar R, Feferman T, Segev O, Yayon A. Monsonego-Ornan E, et al. Among authors: feferman t. Mol Cell Biol. 2000 Jan;20(2):516-22. doi: 10.1128/MCB.20.2.516-522.2000. Mol Cell Biol. 2000. PMID: 10611230 Free PMC article.

2

Overexpression of phosphodiesterases in experimental autoimmune myasthenia gravis: suppression of disease by a phosphodiesterase inhibitor.

Aricha R, Feferman T, Souroujon MC, Fuchs S. Aricha R, et al. Among authors: feferman t. FASEB J. 2006 Feb;20(2):374-6. doi: 10.1096/fj.05-4909fje. Epub 2005 Dec 19. FASEB J. 2006. PMID: 16365386

3

Epitope spreading to hidden cytoplasmic regions of the acetylcholine receptor in experimental autoimmune myasthenia gravis.

Feferman T, Im SH, Fuchs S, Souroujon MC. Feferman T, et al. Ann N Y Acad Sci. 2003 Sep;998:388-90. doi: 10.1196/annals.1254.047. Ann N Y Acad Sci. 2003. PMID: 14592902 No abstract available.

4

Immunosuppression of rat myasthenia gravis by oral administration of a syngeneic acetylcholine receptor fragment.

Maiti PK, Feferman T, Im SH, Souroujon MC, Fuchs S. Maiti PK, et al. Among authors: feferman t. J Neuroimmunol. 2004 Jul;152(1-2):112-20. doi: 10.1016/j.jneuroim.2004.04.010. J Neuroimmunol. 2004. PMID: 15223243

5

Overexpression of IFN-induced protein 10 and its receptor CXCR3 in myasthenia gravis.

Feferman T, Maiti PK, Berrih-Aknin S, Bismuth J, Bidault J, Fuchs S, Souroujon MC. Feferman T, et al. J Immunol. 2005 May 1;174(9):5324-31. doi: 10.4049/jimmunol.174.9.5324. J Immunol. 2005. PMID: 15843529

6

DNA microarray in search of new drug targets for myasthenia gravis.

Feferman T, Aricha R, Menon R, Souroujon MC, Berrih-Aknin S, Fuchs S. Feferman T, et al. Ann N Y Acad Sci. 2007 Jun;1107:111-7. doi: 10.1196/annals.1381.012. Ann N Y Acad Sci. 2007. PMID: 17804538

7

Ex vivo generated regulatory T cells modulate experimental autoimmune myasthenia gravis.

Aricha R, Feferman T, Fuchs S, Souroujon MC. Aricha R, et al. Among authors: feferman t. J Immunol. 2008 Feb 15;180(4):2132-9. doi: 10.4049/jimmunol.180.4.2132. J Immunol. 2008. PMID: 18250419

8

The disease-specific arm of the therapeutic effect of intravenous immunoglobulin in autoimmune diseases: experimental autoimmune myasthenia gravis as a model.

Fuchs S, Feferman T, Meidler R, Brenner T, Laub O, Souroujon MC. Fuchs S, et al. Among authors: feferman t. Isr Med Assoc J. 2008 Jan;10(1):58-60. Isr Med Assoc J. 2008. PMID: 18300576

9

Immunosuppression of EAMG by IVIG is mediated by a disease-specific anti-immunoglobulin fraction.

Fuchs S, Feferman T, Meidler R, Margalit R, Sicsic C, Brenner T, Laub O, Souroujon MC. Fuchs S, et al. Among authors: feferman t. Ann N Y Acad Sci. 2008;1132:244-8. doi: 10.1196/annals.1405.032. Ann N Y Acad Sci. 2008. PMID: 18567875

10

Suppression of experimental autoimmune myasthenia gravis by combination therapy: pentoxifylline as a steroid-sparing agent.

Menon RT, Feferman T, Aricha R, Souroujon MC, Fuchs S. Menon RT, et al. Among authors: feferman t. J Neuroimmunol. 2008 Sep 15;201-202:128-35. doi: 10.1016/j.jneuroim.2008.05.023. Epub 2008 Jul 15. J Neuroimmunol. 2008. PMID: 18632163

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results